ATTO.US Attovia Therapeutics, Inc. Common Stock

Healthcare Biotechnology USA Stocks
15.13 USD
Close of Nov 14, 2026
12.94 28.00
Market cap
USD 692M
P/E
-
P/B
-
ROE
-20.7%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is ATTO.US undervalued?

Graham number

The Graham number of Attovia Therapeutics, Inc. Common Stock cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Attovia Therapeutics, Inc. Common Stock fundamental analysis

No fundamental analysis for Attovia Therapeutics, Inc. Common Stock yet.

Attovia Therapeutics, Inc. Common Stock stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Attovia Therapeutics, Inc. Common Stock

Attovia Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops biotherapeutics for immune-mediated diseases in the United States. The company provides ATTOBODY, a biparatopic biologics platform designed to deliver improved treatments. The company's products include ATTO-1310, a novel ATTOBODY-based Fc-fusion protein therapeutic that inhibits IL-31; developed for the treatment of chronic pruritic diseases such as CPUO, high-itch AD, cholestatic pruritus, and…

Full company profile